Nevrivy Patent Law Group Receives Legal Award for Sustained Excellence in Biotech and Pharmaceutical Patents – USA from Acquisition International

We are very pleased to announce that we have been named a recipient of a legal award from Acquisition International, a media company that focuses on corporate finance, winning in the category of Sustained Excellence in Biotech and Pharmaceutical Patents – USA for 2015.


Information about our firm appears on pages 14 and 15 of the publication:


About Acquisition International Legal Awards


Since 2010, Acquisition International Magazine’s annual awards have been highlighting the amazing work done by those firms and individuals whose ceaseless dedication to innovation, customer care and the continued growth and improvement of their businesses has seen them forge ahead of their competitors and raise the bar for performance and results in their industry.


We pride ourselves – and rightly so – on the validity of our awards and winners, an approach that is reflected in the rigorous and tightly monitored nomination, judging and selection processes. Every one of our awards is given solely on merit, meaning that there are no commercial requirements, no awards guaranteed by payment and no barriers to entry. In other words, no matter how big or small the business and regardless of where it is based, the only factors that will determine success are the work that is done and the results achieved.


Each and every nomination is subject to a lengthy and in-depth assessment process, designed to enable us to separate the truly remarkable from their peers.


The process begins the second we open the ballot boxes and distribute the voting forms to our worldwide network of partners and industry experts and sees us combine the votes received – alongside submitted supporting evidence, our own in-house research and the in-depth knowledge and expertise of our network of corporate leaders and experts to arrive at our final winners list.


This comprehensive selection and judging process ensures that our awards are always a true representation of the market in question and that all of our winners are truly at the cutting edge of their respective industries.


Recent articles, interviews or news items involving the firm or its attorneys include:

Our firm will be attending the Biotechnology Industry Association (BIO) conference in San Diego, June, 2014.

Keisha Hylton-Rodic, Ph.D. will be moderating an American Bar Association webinar entitled “The Nuts and Bolts of Patents and the Drug Approval Process,” November, 2013.

Our firm is pleased to exhibit at the American Chemical Society national meeting in Indianapolis, September, 2013.

Our firm hosts a delegation of Senior Examiners from the European Patent Office for an educational event entitled “A Conversation with EPO Examiners,” May, 2013.

“Lawyers Offer Predictions for Myriad, Diagnostic Field Based on Supreme Court’s Decision Against Prometheus ”
Genetic Engineering & Biotechnology News

Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster, FiercePharma

“Caveats in Patent Overhaul Could Pose New Challenges for Smaller Biopharmas”
Genetic Engineering & Biotechnology News

“Implementation of European Court Decision to Ban hESC Patents Depends on National Patent Offices”
Genetic Engineering & Biotechnology News

Nevrivy Patent Law Group is exhibiting at the 2011 Entrepreneur Expo, November 14, 2011.

“Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation”Genetic Engineering & Biotechnology News, June 2011

IP Man III, Legal Bisnow (New York) (profiling Sullivan’s IP Law Outline)

IP Lawyers Don’t Need Desks, Legal Bisnow (Washington, D.C.) (profiling Sullivan’s IP Law Outline)

“Kelli Watson Francuzenko, Life Science IP Transactional Attorney, Joins Nevrivy Patent Law Group,” Intellectual Property Today

“China gets serious about biotech,” FierceBiotech

Nevrivy Patent Law Group is sponsoring the World Stem Cell Summit, held September 21-23 in Baltimore, Maryland.

“Restoring Science to its Rightful Place in America,” Law360

“Does the U.S. biotech industry deserve a bailout?” FiercePharma and FierceBiotech